1. Home
  2. CRVS vs NCA Comparison

CRVS vs NCA Comparison

Compare CRVS & NCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRVS
  • NCA
  • Stock Information
  • Founded
  • CRVS 2014
  • NCA 1987
  • Country
  • CRVS United States
  • NCA United States
  • Employees
  • CRVS N/A
  • NCA N/A
  • Industry
  • CRVS Biotechnology: Pharmaceutical Preparations
  • NCA Investment Managers
  • Sector
  • CRVS Health Care
  • NCA Finance
  • Exchange
  • CRVS Nasdaq
  • NCA Nasdaq
  • Market Cap
  • CRVS 305.4M
  • NCA 279.1M
  • IPO Year
  • CRVS 2016
  • NCA N/A
  • Fundamental
  • Price
  • CRVS $4.17
  • NCA $8.47
  • Analyst Decision
  • CRVS Strong Buy
  • NCA
  • Analyst Count
  • CRVS 4
  • NCA 0
  • Target Price
  • CRVS $15.00
  • NCA N/A
  • AVG Volume (30 Days)
  • CRVS 437.5K
  • NCA 59.6K
  • Earning Date
  • CRVS 08-12-2025
  • NCA 01-01-0001
  • Dividend Yield
  • CRVS N/A
  • NCA 3.92%
  • EPS Growth
  • CRVS N/A
  • NCA N/A
  • EPS
  • CRVS N/A
  • NCA N/A
  • Revenue
  • CRVS N/A
  • NCA N/A
  • Revenue This Year
  • CRVS N/A
  • NCA N/A
  • Revenue Next Year
  • CRVS N/A
  • NCA N/A
  • P/E Ratio
  • CRVS N/A
  • NCA N/A
  • Revenue Growth
  • CRVS N/A
  • NCA N/A
  • 52 Week Low
  • CRVS $2.47
  • NCA $7.77
  • 52 Week High
  • CRVS $10.00
  • NCA $9.12
  • Technical
  • Relative Strength Index (RSI)
  • CRVS 46.72
  • NCA 45.98
  • Support Level
  • CRVS $4.58
  • NCA $8.51
  • Resistance Level
  • CRVS $4.98
  • NCA $8.56
  • Average True Range (ATR)
  • CRVS 0.23
  • NCA 0.08
  • MACD
  • CRVS -0.02
  • NCA -0.01
  • Stochastic Oscillator
  • CRVS 8.52
  • NCA 25.00

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

About NCA Nuveen California Municipal Value Fund

Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. Its primary objective is to provide current income exempt from regular federal and California income taxes. The fund's secondary objective is to enhance portfolio value relative to the California municipal bond market by investing in tax-exempt California municipal securities that the Fund's investment adviser and/or the Fund's sub-adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

Share on Social Networks: